PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

医学 恩扎鲁胺 前列腺癌 内科学 危险系数 安慰剂 临床终点 雄激素剥夺疗法 多西紫杉醇 醋酸阿比特龙酯 肿瘤科 无进展生存期 奥拉帕尼 中期分析 置信区间 随机对照试验 雄激素受体 癌症 化疗 病理 聚ADP核糖聚合酶 化学 替代医学 基因 聚合酶 生物化学
作者
Fred Saad,Andrew J. Armstrong,Antoine Thiery-Vuillemin,Mototsugu Oya,Eugenia Loredo,Giuseppe Procopio,J. Menezes,Gustavo Girotto,Cagatay Arslan,Niven Mehra,Francis Parnis,Emma Brown,Friederike Schlürmann,Jae Young Joung,Mikio Sugimoto,Christian Poehlein,Elizabeth A. Harrington,Chintu Desai,Jinyu Kang,Noel W. Clarke
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (6_suppl): 11-11 被引量:41
标识
DOI:10.1200/jco.2022.40.6_suppl.011
摘要

11 Background: Preclinical studies have shown combined anti-tumor effect through interactions between poly(adenosine diphosphate–ribose) polymerase and androgen receptor signaling pathways. A Phase II trial (NCT01972217) in pts with mCRPC unselected by homologous recombination repair (HRR) status who previously received docetaxel demonstrated improved radiographic progression-free survival (rPFS) for pts treated with ola + abi vs pbo + abi (Clarke N, 2018). The Phase III PROpel study (NCT03732820) evaluates the efficacy and safety of ola + abi in the 1L mCRPC setting. Methods: PROpel is a randomized, double-blind, placebo-controlled Phase III trial in pts with mCRPC undergoing 1L treatment after failure of primary androgen deprivation therapy, enrolled independent of HRR status. Pts were randomized 1:1 to receive ola (300 mg twice daily [bid]) or pbo, and abi (1000 mg once daily) + prednisone or prednisolone (5 mg bid). The primary endpoint was investigator-assessed rPFS with multiple secondary endpoints, including overall survival (OS). Results:796 pts were randomized to ola + abi (n=399) or pbo + abi (n=397).In this planned interim analysis, 1L treatment with ola + abi significantly prolonged rPFS vs pbo + abi in pts with mCRPC irrespective of HRR status (24.8 vs 16.6 months; hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.54–0.81; P <0.0001). Predefined subgroup analyses showed rPFS improvement across all subgroups, including pts with (HR 0.54, 95% CI 0.36–0.79) and without (HR 0.76, 95% CI 0.59–0.97) HRR mutations detected by circulating tumor DNA testing. A sensitivity analysis of rPFS by blinded independent central review was consistent with the primary analysis (HR 0.61, 95% CI 0.49–0.74; P=0.004). OS is currently immature with 228 deaths (28.6%). A trend in OS favoring ola + abi was observed (HR 0.86, 95% CI 0.66–1.12). Secondary endpoints of time to first subsequent treatment (HR 0.74, 95% CI 0.61–0.90) and time to second progression-free survival or death (HR 0.69, 95% CI 0.51–0.94) were supportive of long-term benefits. The most common grade ≥3 adverse event (AE) reported was anemia (15.1 vs 3.3%) for ola + abi vs pbo + abi; 13.8 vs 7.8% pts, respectively, discontinued ola/pbo because of an AE. The rate of AEs leading to abi discontinuation were similar in both arms (8.5 vs 8.8%). Conclusions: At interim analysis, PROpel met its primary objective, demonstrating significant improvement in rPFS for ola + abi vs pbo + abi in pts with newly detected mCRPC who had not received prior 1L therapy, irrespective of HRR status. The safety and tolerability profile of ola + abi was consistent with the known safety profiles of the individual drugs. These results demonstrate the benefit of ola + abi without the need for HRR stratification in 1L treatment of mCRPC. Pt follow-up is ongoing for the planned OS analysis. Clinical trial information: NCT03732820.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彪yu发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
焜少完成签到,获得积分10
3秒前
ladder发布了新的文献求助10
3秒前
改论文不看剧完成签到,获得积分10
3秒前
3秒前
pcm发布了新的文献求助10
3秒前
打工不可能完成签到,获得积分10
4秒前
IU冰冰完成签到 ,获得积分10
4秒前
重要的班发布了新的文献求助20
4秒前
Mine发布了新的文献求助10
5秒前
泡泡完成签到,获得积分10
5秒前
5秒前
ZZ发布了新的文献求助10
5秒前
Gumiano发布了新的文献求助10
6秒前
风趣银耳汤关注了科研通微信公众号
6秒前
6秒前
7秒前
111完成签到,获得积分20
7秒前
8秒前
8秒前
禾苗发布了新的文献求助10
9秒前
9秒前
_hhhjhhh发布了新的文献求助30
9秒前
Diaory2023完成签到 ,获得积分0
9秒前
阮楷瑞发布了新的文献求助10
9秒前
沐溪完成签到,获得积分10
10秒前
啦啦啦~发布了新的文献求助10
10秒前
小吴同志发布了新的文献求助10
10秒前
10秒前
调皮的胜关注了科研通微信公众号
11秒前
11秒前
Muxi发布了新的文献求助20
11秒前
锅包肉爱吃肉完成签到 ,获得积分10
12秒前
Lionel完成签到,获得积分10
13秒前
wzt发布了新的文献求助10
13秒前
可爱的函函应助90采纳,获得10
13秒前
ED应助易琚采纳,获得10
13秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974559
求助须知:如何正确求助?哪些是违规求助? 3518949
关于积分的说明 11196503
捐赠科研通 3255066
什么是DOI,文献DOI怎么找? 1797673
邀请新用户注册赠送积分活动 877076
科研通“疑难数据库(出版商)”最低求助积分说明 806130